Patrick P. Mcdonald
Sherbrooke, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
A feedback loop sustaining neutrophil extracellular trap formation involves S100 proteins, histones, TLR2 and RAGE, and is restrained by albumin.
Journal: Frontiers in immunology
Published: December 23, 2025
Impact of dipeptidyl peptidase I and neutrophil serine proteases on neutrophil functional responses.
Impact of dipeptidyl peptidase I and neutrophil serine proteases on neutrophil functional responses.
Journal: Frontiers in pharmacology
Published: August 20, 2025
Ligation of TLR2, but not of TLR4 or other Toll-like receptors, induces neutrophil extracellular trap formation in humans.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 27, 2025
Recombinant chymase inhibits fibrinolysis induced by endogenous plasmin in clotted human blood.
Journal: Frontiers in immunology
Published: October 15, 2024
Neutrophilic inflammation in bronchiectasis.
Journal: European respiratory review : an official journal of the European Respiratory Society
Published: August 06, 2024
Protective effects of neutrophil serine protease inhibition against ischemia-reperfusion injury in lung or heart transplantation.
Journal: The FEBS journal
Published: June 19, 2024
Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.
Journal: Frontiers in pharmacology
Published: March 06, 2024
Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases).
Journal: Biochemical pharmacology
Published: November 09, 2023
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
Journal: Frontiers in immunology
Published: May 29, 2023
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Journal: Frontiers in pharmacology
Published: April 20, 2023
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Journal: Frontiers in immunology
Published: March 13, 2023
Last Updated: 09/26/2026